Lavomax tablets 125mg 6 pcs and similar items

Short description Antiviral immunostimulating agent. In adults: viral hepatitis A, B, C, herpes and CMV infection, complex therapy: infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis), chlamydial infections of urogenital and respiratory infections; and other ARVI. In children over 7 years old: treatment of influenza and other ARVI. pharmachologic effect Antiviral and immunomodulatory drug. Lavomax stimulates the formation of ?-, ?-, ?-interferons in the body. In response to the introduction of Lavomax, interferon is produced mainly by intestinal epithelial cells, hepatocytes, T-lymphocytes and neutrophils. After taking the drug inside, the maximum production of interferon is determined in the intestine-liver-blood sequence after 4-24 hours. Lavomax has an immunomodulatory and antiviral effect. Stimulates bone marrow stem cells, increases antibody production depending on the dose, reduces the degree of immunosuppression, restores the T-helper / T-suppressor ratio. Effective against various viral infections, incl. against influenza viruses, other acute respiratory viral infections, hepatitis and herpes viruses, cytomegaloviruses and neurotropic viruses. The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed. Indications The drug is used in adults as part of complex therapy: - viral hepatitis A, B and C; - herpes infection; - cytomegalovirus infection; - infectious-allergic and viral encephalomyelitis; - urogenital and respiratory chlamydia; - non-gonococcal urethritis; - pulmonary tuberculosis. Treatment and prevention of influenza and other acute respiratory viral infections. Method of administration and dosage The drug is taken orally, after meals. In the treatment of influenza and other acute respiratory viral infections - in the first two days of the disease - 125 mg, then every other day, 125 mg. Heading dose - 750 mg (for a course of treatment - 6 tablets, 125 mg each). For the prevention of influenza and other acute respiratory viral infections - 125 mg once a week for 6 weeks. For the course of treatment - 6 tab. 125 mg each. For the treatment of viral hepatitis A - the first day, 125 mg 2 times, then 125 mg every other day. Heading dose - 1.25 g (for a course of treatment - 10 tablets, 125 mg each). For the treatment of acute hepatitis B - the first and second days, 125 mg, then 125 mg every other day. Heading dose - 2 g (for a course of treatment - 16 tablets, 125 mg each), with a prolonged course of hepatitis B - 125 mg 2 times / day on the first day, then 125 mg every other day. The course dose is 2.5 g (for a course of treatment - 20 tablets, 125 mg each). In chronic hepatitis B - the initial phase of treatment (2.5 g) - the first two days, 250 mg each, then 125 mg every other day. Continuation phase (from 1.25 g to 2.5 g) - 125 mg per week. The course dose of Lavomax is from 3.75 to 5 g (for a course of treatment - from 30 to 40 tablets, 125 mg each), the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process. In acute hepatitis C - the first and second days, 125 mg, then 125 mg every other day. Heading dose - 2.5 g (for a course of treatment - 20 tablets, 125 mg each). In chronic hepatitis C - the initial phase of treatment (2.5 g) - the first two days, 250 mg each, then 125 mg every other day. Continuation phase (2.5 g) - 125 mg per week. The course dose of Lavomax is 5 g (for a course of treatment - 40 tablets, 125 mg each). The duration of therapy is 6 months, depending on the results of biochemical, immunological, morphological markers of the process activity. For the treatment of herpes, cytomegalovirus infection - the first two days, 125 mg, then every other day, 125 mg. Heading dose - 2.5 g (for a course of treatment - 20 tablets, 125 mg each). With urogenital and respiratory chlamydia, non-gonococcal urethritis - the first two days, 125 mg, then every other day, 125 mg. Heading dose - 1.25 g (for a course of treatment - 10 tablets, 125 mg each). As part of the complex therapy of pulmonary tuberculosis - the first two days, 250 mg, then 125 mg every other day. Heading dose - 2.5 g (for a course of treatment - 20 tablets, 125 mg each). As part of the complex therapy of neuroviral infections, the dose is set individually, the course of treatment is 4 weeks. Side effects Possible: short-term chills, allergic reactions, symptoms of dyspepsia. Contraindications - pregnancy; - lactation period (breastfeeding); - children and adolescents up to 18 years old; - deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption (the drug contains sucrose); - hypersensitivity to the components of the drug. Overdose Overdose cases of Lavomax are unknown. special instructions Influence on the ability to drive vehicles and control mechanisms The use of the drug does not affect the ability to drive vehicles and engage in other sweat Potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions. Interaction with other drugs No clinically significant interaction of Lavomax with antibiotics, standard therapy for viral and bacterial diseases, alcohol has been identified. Compatible with antibiotics and standard therapy for viral and bacterial diseases. Storage conditions The drug should be stored out of the reach of children, in a dry, dark place at a temperature not exceeding 25 C. Shelf life is 2 years.